Features Partner Sites Information LinkXpress
Sign In
Demo Company

Compact Benchtop System Enables Preparative Protein Purification in any Laboratory

By BiotechDaily International staff writers
Posted on 03 Dec 2013
Print article
Image: The ÄKTA start protein purification system with the Frac30 fraction collector (Photo courtesy of GE Life Sciences).
Image: The ÄKTA start protein purification system with the Frac30 fraction collector (Photo courtesy of GE Life Sciences).
A compact preparative chromatography instrument that is compatible with prepacked or user prepared columns and can be combined with fraction collectors to generate a complete protein purification system in any biotech or life sciences laboratory is now on the market.

The GE Healthcare (Chalfont St. Giles, United Kingdom) ÄKTA start is designed as a stand-alone system that combines a front-facing flow path with a user-friendly interface. The system is controlled via an intuitive touchscreen, which displays the UV curve and other run data in real-time.

ÄKTA start is compatible with all common purification techniques, including affinity and ion exchange chromatography, desalting, buffer exchange, and gel filtration. The system supports purification of tagged proteins, antibodies, untagged or native proteins, and sample clean-up applications. ÄKTA start can be operated using predefined quick-start protocols, built-in templates, or by creating custom protocols. Prepacked columns are available for common applications.

The ÄKTA start instrument can be augmented with GE Healthcare's Frac30 fraction collector for automatic protein collection, and with user-friendly UNICORN start 1.0 control software, which provides additional evaluation tools and the ability to control ÄKTA start from a computer.

Related Links:

GE Healthcare

Print article



view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

How Blocking TROY Signaling Slows Brain Cancer Growth

Cancer researchers have found how the low molecular weight drug propentofylline (PPF) slows the growth of the aggressive brain tumor glioblastoma multiforme (GBM). This form of brain cancer is the most... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.